Medical AI Alliance
← Company Index
Pharma & CDMOKOSPI 005500392 approvals60 trials

SAMJIN PHARMACEUTICAL CO.,LTD

Official website

Founded in 1968 and listed on KOSPI in 1988, Samjin Pharmaceutical makes Geworin, Trestan, and Plaris while pursuing new drug R&D.

As of 2026-10-09, SAMJIN PHARMACEUTICAL CO.,LTD has 392 Korean MFDS drug approvals, 7 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Samjin Pharmaceutical was founded in 1968 and listed on the KOSPI in 1988. It makes the OTC analgesic Geworin and appetite stimulant Trestan, and prescription drugs including the antiplatelet agent Plaris and the cerebral function enhancer Neutyrin, while expanding into health functional foods, cosmetics, and medical devices. It built an EU-GMP injectable line at its Osong API plant, completed in November 2022 with GMP approval obtained in June 2024, and in March 2023 signed a KRW 100 billion license-in agreement with Aribio Co., Ltd. for the Alzheimer's drug candidate AR1001.

Products & technology

  • Geworinanti-inflammatory analgesic
  • Trestanappetite stimulant
  • Plarisantiplatelet agent
  • Neutyrincerebral function enhancer

Regulatory approvals

data.go.kr

392 Korean MFDS drug approvals · 1959–2026

  • MFDS drugSoo Kyungokgo2026-08-31
    Drug · OTC · Notification202602550
  • MFDS drugLexaban Tab. 60mg2026-08-11
    Drug · Prescription · Approval202602333
  • MFDS drugLexaban Tab. 30mg2026-08-11
    Drug · Prescription · Approval202602334
  • MFDS drugLexaban Tab. 15mg2026-08-11
    Drug · Prescription · Approval202602335
  • MFDS drugNeustazet-R Orally Disintegrating Tab. 10/10 mg2026-06-30
    Drug · Prescription · Approval202601900
  • MFDS drugNeustazet-R Orally Disintegrating Tab. 10/20 mg2026-06-30
    Drug · Prescription · Approval202601901
  • MFDS drugNeustazet-R Orally Disintegrating Tab. 10/5 mg2026-06-30
    Drug · Prescription · Approval202601902
  • MFDS drugSamjin Pancreatin Tab. 250002026-06-29
    Drug · OTC · Approval202601847
  • MFDS drugVonojin Tab. 10mg2026-05-27
    Drug · Prescription · Approval202601515
  • MFDS drugVonojin Tab. 20mg2026-05-27
    Drug · Prescription · Approval202601516
  • MFDS drugWetego2026-04-20
    Drug · Prescription · Approval202601124
  • MFDS drugWetego Tab. 50mg2026-04-20
    Drug · Prescription · Approval202601125
Show 68 more
  • MFDS drugE-Bam Easy Soft Cap.2026-03-23
    Drug · OTC · Notification202600823
  • MFDS drugNEUTOIN Tab. 3mg2026-03-20
    Drug · Prescription · Approval202600801
  • MFDS drugMagnecore Softcap.2026-03-17
    Drug · OTC · Notification202600776
  • MFDS drugNeutoin Duo Tab. 10/20 mg2026-03-05
    Drug · Prescription · Approval202600664
  • MFDS drugEpilatam XR Tablet 1000 mg2026-02-26
    Drug · Prescription · Approval202600594
  • MFDS drugFulveserd Prefilled Injection(Fulvestrant)2026-02-13
    Drug · Prescription · Approval202600431
  • MFDS drugExvan Tab. 40mg2025-09-24
    Drug · Prescription · Approval202502531
  • MFDS drugBricetam Tab. 50mg2025-09-23
    Drug · Prescription · Approval202502516
  • MFDS drugBricetam Tab. 100mg2025-09-23
    Drug · Prescription · Approval202502517
  • MFDS drugBricetam Tab. 10mg2025-09-23
    Drug · Prescription · Approval202502518
  • MFDS drugBricetam Tab. 25mg2025-09-23
    Drug · Prescription · Approval202502519
  • MFDS drugEmpozin Duo XR Tab. 5/1000mg2025-07-31
    Drug · Prescription · Approval202502002
  • MFDS drugEmpozin Duo XR Tab. 12.5/1000mg2025-07-31
    Drug · Prescription · Approval202502003
  • MFDS drugEmpozin Duo XR Tab. 10/1000mg2025-07-25
    Drug · Prescription · Approval202501909
  • MFDS drugEmpozin Duo XR Tab. 25/1000mg2025-07-25
    Drug · Prescription · Approval202501910
  • MFDS drugTofanus Tab. 5mg2025-07-25
    Drug · Prescription · Approval202501934
  • MFDS drugTofanus Tab. 10mg2025-07-25
    Drug · Prescription · Approval202501935
  • MFDS drugHeroCool Powder2025-06-26
    Drug · OTC · Notification202501583
  • MFDS drugLock Cold-cough Syr.2025-05-21
    Drug · OTC · Notification202501249
  • MFDS drugLock Cold-total Syr.2025-05-21
    Drug · OTC · Notification202501250
  • MFDS drugLock Cold-nose Syr.2025-05-08
    Drug · OTC · Notification202501118
  • MFDS drugFetra Tab. (Letrozole)2024-12-23
    Drug · Prescription · Approval202403042
  • MFDS drugParnus Tab. 240mg2024-11-13
    Drug · OTC · Notification202402684
  • MFDS drugBACAVIR Tab. 0.5mg2024-11-08
    Drug · Prescription · Approval202402655
  • MFDS drugAlltin Tab. 5mg (Biotion)2024-10-08
    Drug · OTC · Notification202402399
  • MFDS drugGewofit Max Plasta (Flurbiprofen)2024-05-24
    Drug · OTC · Notification202401286
  • MFDS drugSamjin DRON Tab.2024-05-10
    Drug · Prescription · Approval202401156
  • MFDS drugCleadam Tab.2024-05-01
    Drug · OTC · Notification202401075
  • MFDS drugLigenta-Duo XR Tab. 5/1000mg2024-03-22
    Drug · Prescription · Approval202400610
  • MFDS drugLigenta-Duo XR Tab. 2.5/1000mg2024-03-22
    Drug · Prescription · Approval202400611
  • MFDS drugGEWOFIT Strong Cataplasma (Diclofenac Sodium)2024-03-18
    Drug · OTC · Notification202400559
  • MFDS drugIcechon Eye drops2024-01-25
    Drug · OTC · Notification202400201
  • MFDS drugAllerjin Tab. 60 mg2023-11-06
    Drug · OTC · Approval202303068
  • MFDS drugLock Cold Sol.2023-10-16
    Drug · OTC · Notification202302922
  • MFDS drugNeustatin TS Tab. 80/5/5mg2023-09-25
    Drug · Prescription · Approval202302812
  • MFDS drugNeustatin-TS 40/5/5mg2023-09-25
    Drug · Prescription · Approval202302813
  • MFDS drugEmpozin Duo Tab. 12.5/1000mg2023-09-11
    Drug · Prescription · Approval202302698
  • MFDS drugEmpozin Duo Tab. 12.5/850mg2023-09-11
    Drug · Prescription · Approval202302699
  • MFDS drugEmpozin Duo Tab. 12.5/500mg2023-09-11
    Drug · Prescription · Approval202302700
  • MFDS drugArthbone plus Tab.2023-08-10
    Drug · Prescription · Approval202302411
  • MFDS drugSamjin Sildenafil citrate Tab. 20mgRevoked2023-07-07
    Drug · Prescription · Approval202302072
  • MFDS drugDapozin M XR Tab. 10/500mg2023-06-21
    Drug · Prescription · Approval202301904
  • MFDS drugCHONMAX Tab2023-06-09
    Drug · OTC · Notification202301790
  • MFDS drugFOVIGL Tablet 10/100mg2023-03-31
    Drug · Prescription · Approval202301100
  • MFDS drugNeustatin-R Tab. 2.5mg (Rosuvastatin calcium)2023-03-21
    Drug · Prescription · Approval202300974
  • MFDS drugMaciten Tab. 10mg2023-03-16
    Drug · Prescription · Approval202300945
  • MFDS drugTAFLEAD Tab.2023-03-15
    Drug · Prescription · Approval202300925
  • MFDS drugFima Duo 60/5mg2023-01-06
    Drug · Prescription · Approval202300102
  • MFDS drugFima Duo Tab. 60/2.5mg2023-01-06
    Drug · Prescription · Approval202300120
  • MFDS drugFima Duo Tab. 30/2.5mg2023-01-06
    Drug · Prescription · Approval202300138
  • MFDS drugDapozin M XR Tab. 10/1000mg2023-01-06
    Drug · Prescription · Approval202300154
  • MFDS drugSinuvi M XR Tab. 50/500mg2022-05-11
    Drug · Prescription · Approval202201964
  • MFDS drugSinuvi M XR Tab. 50/1000mg2022-05-11
    Drug · Prescription · Approval202201965
  • MFDS drugSinuvi M XR Tab. 100/1000mg2022-05-11
    Drug · Prescription · Approval202201966
  • MFDS drugEmpozin Duo Tab. 5/1000mg2022-04-13
    Drug · Prescription · Approval202201538
  • MFDS drugEmpozin Duo Tab. 5/850mg2022-04-13
    Drug · Prescription · Approval202201539
  • MFDS drugEmpozin Duo Tab. 5/500mg2022-04-13
    Drug · Prescription · Approval202201540
  • MFDS drugZolent inj. 5mg/100ml2022-03-07
    Drug · Prescription · Approval202200967
  • MFDS drugAnafachi Tablet2022-02-16
    Drug · OTC · Notification202200721
  • MFDS drugSinuvi M Tab. 50/500mg2022-01-28
    Drug · Prescription · Approval202200503
  • MFDS drugSinuvi M Tab. 50/850mg2022-01-28
    Drug · Prescription · Approval202200504
  • MFDS drugSinuvi M Tab. 50/1000mg2022-01-28
    Drug · Prescription · Approval202200505
  • MFDS drugRabeol Duo Tab. 20/500mg2022-01-27
    Drug · Prescription · Approval202200472
  • MFDS drugEpilatam XR Tablet 500mg2022-01-24
    Drug · Prescription · Approval202200401
  • MFDS drugVilguard Tab. 50 mg2022-01-20
    Drug · Prescription · Approval202200365
  • MFDS drugRabeol Duo Tab. 10/500mg2021-12-31
    Drug · Prescription · Approval202108208
  • MFDS drugGEWORIN V Tablet2021-11-16
    Drug · OTC · Notification202107495
  • MFDS drugBTENTIAL Tab.Revoked2021-11-02
    Drug · OTC · Notification202107250

Showing the 80 most recent of 392 records.

Clinical trials

data.go.kr

60 MFDS clinical trial authorisations · 2012–2026 (Bioequivalence 46 · Phase 1 11 · Phase 2 2 · Phase 2a 1)

  • BioequivalenceSJP3612026-04-28

    2 trial sites

  • BioequivalenceSJP3772026-04-27

    2 trial sites

  • BioequivalenceSJP3612025-09-19

    2 trial sites

  • BioequivalenceSJP3722025-09-08

    2 trial sites

  • BioequivalenceSJP3722025-09-08

    2 trial sites

  • BioequivalenceSJP3542025-04-25

    2 trial sites

  • BioequivalenceSJP3212024-11-01

    2 trial sites

  • BioequivalenceSJP3642024-06-25

    2 trial sites

  • Phase 1SJP0152024-05-27

    2 trial sites

  • Phase 1SJP0152024-05-24

    2 trial sites

  • BioequivalenceSJP3602023-11-01

    1 trial site

  • BioequivalenceSJP3392023-06-01

    2 trial sites

Show 48 more
  • Bioequivalence에이알비정(로사르탄칼륨)2022-06-09

    2 trial sites

  • BioequivalenceSJP3332022-03-04

    2 trial sites

  • Phase 1SJP0102022-02-24

    2 trial sites

  • Bioequivalence페소린정80밀리그램(페북소스타트)2022-01-25

    2 trial sites

  • Bioequivalence시너젯이알서방정2021-12-28

    1 trial site

  • Bioequivalence시너젯이알서방정2021-11-23

    1 trial site

  • Phase 1SJP1804점안액0.25%2021-11-22

    1 trial site

  • Phase 1SJP0062021-11-05

    2 trial sites

  • Bioequivalence에이알비정(로사르탄칼륨)2021-08-19

    2 trial sites

  • Bioequivalence네메올정40밀리그램(에스오메프라졸마그네슘삼수화물)2021-07-22

    2 trial sites

  • Bioequivalence라베올정20밀리그램(라베프라졸나트륨)2021-06-09

    2 trial sites

  • BioequivalenceSJP3212021-05-21

    2 trial sites

  • Bioequivalence크리페낙정(아세클로페낙)2021-01-22

    1 trial site

  • Bioequivalence엘사반정5밀리그램(아픽사반)2021-01-14

    2 trial sites

  • Phase 1SJP1604주2021-01-07

    1 trial site

  • Bioequivalence에필라탐서방정750밀리그램(레비티라세탐)2020-11-12

    2 trial sites

  • Bioequivalence엑스반정160밀리그램(발사르탄)2020-11-06

    2 trial sites

  • Bioequivalence글레존정(피오글리타존염산염)2020-10-13

    2 trial sites

  • BioequivalenceSJP3212020-10-08

    1 trial site

  • Bioequivalence에필라탐서방정750밀리그램(레비티라세탐)2020-07-17

    2 trial sites

  • BioequivalenceSJP0072020-06-08

    2 trial sites

  • Bioequivalence세로카바정20밀리그램(에스시탈로프람옥살산염)2020-05-08

    2 trial sites

  • Bioequivalence리복사반정2.5밀리그램(리바록사반)2020-04-03

    2 trial sites

  • Phase 2aSA0012019-11-06

    4 trial sites

  • Bioequivalence뉴티린정(콜린알포세레이트)2019-07-11

    2 trial sites

  • Phase 1SJP0032018-12-05

    1 trial site

  • Bioequivalence삼진리바록사반정20mg2018-10-02

    2 trial sites

  • Bioequivalence인트랙정12.5밀리그램2018-03-16

    2 trial sites

  • Phase 2SA0012017-09-18

    6 trial sites

  • Phase 2SJP0022017-09-06

    6 trial sites

  • Bioequivalence플래리스플러스정2016-09-09

    2 trial sites

  • Bioequivalence인트랙정(카르베딜롤)2016-09-07

    2 trial sites

  • Bioequivalence삼진리나글립틴듀오정 2.5/1000mg2016-09-06

    2 trial sites

  • Bioequivalence뉴토인정23밀리그램(도네페질염산염수화물)2016-08-18

    2 trial sites

  • Phase 1SJP0022016-07-01

    1 trial site

  • Bioequivalence삼진리나글립틴정2016-05-24

    2 trial sites

  • Phase 1SA0012016-05-18

    1 trial site

  • Bioequivalence삼진테노포비르에프정(테노포비르디소프록실푸마르산염)2015-12-03

    2 trial sites

  • Bioequivalence플래리스플러스캡슐2015-12-03

    2 trial sites

  • Bioequivalence삼진티카그렐러정2015-11-27

    2 trial sites

  • Bioequivalence뉴토인정(도네페질염산염)2015-06-30

    2 trial sites

  • Phase 1SA0012015-04-17

    1 trial site

  • Bioequivalence삼진타다라필정20밀리그램(가칭)(타다라필)2014-08-08

    2 trial sites

  • Bioequivalence뉴스타틴에이정40밀리그램(아토르바스타틴칼슘삼수화물)2014-07-07

    2 trial sites

  • Bioequivalence삼진둘록세틴캡슐60밀리그램(둘록세틴염산염)2013-11-14

    2 trial sites

  • Bioequivalence뉴스타틴-알정10밀리그램(로수바스타틴칼슘)2013-06-05

    1 trial site

  • Bioequivalence에이알비-에이디 10/160mg(가칭)2012-09-27
  • Phase 1플래리스플러스캡슐2012-01-12

    1 trial site

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

에이즈 치료제 개발 · AIDS(예방제) · 미국FDA IND 승인 후 임상 1상시험 준비중 · License-out to Imquest Pharmaceuticals, Inc. for worldwide rights (Samjin holds exclusive domestic rights), signed 2005-10-14

항암제 개발 · 암 · 기술이전 후 미국FDA IND 신청을 위한 전임상 자료준비중 · License-out to Imquest Pharmaceuticals, Inc. for worldwide rights (Samjin holds exclusive domestic rights), signed 2006-04-25

AR1001 · 알츠하이머병 · 글로벌 임상 3상 · License-in from Aribio Co., Ltd., signed 2023-03-06, total contract value KRW 100 billion, amount paid KRW 10 billion

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched

Patents

KIPRIS · applicant-matched
Show 179 more patents

AI reads

MAA server logs · IP-verified
78
Times AI engines pulled SAMJIN PHARMACEUTICAL CO.,LTD's records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

2
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

76
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

12
live 0
Last 7 days
56
live 1
Last 30 days
78
live 2
All time
  • OpenAIChatGPT-Userlive2
  • OpenAIOAI-SearchBot68
  • PerplexityPerplexityBot4
  • AnthropicClaudeBot2
  • MicrosoftBingbot1
  • GoogleGoogleOther1

Measured since Aug 26, 2026 · 5 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for SAMJIN PHARMACEUTICAL CO.,LTD and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies in the same categoryPharma & CDMO

ILDONG HOLDINGS CO.,LTD100

Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.

Yuyu Pharma, Inc.100

Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.

IL DONG PHARMACEUTICAL CO., LTD.100

Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.

Medy-Tox Inc.99

Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.

GC Biopharma Corp.97

KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.

DAEWON PHARMACEUTICAL CO.,LTD85

KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.

SAMSUNG BIOLOGICS CO.,LTD.85

Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.

GENOLUTION INC.85

Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.

AHN-GOOK PHARMACEUTICAL Co., Ltd.85

Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.

CORESTEMCHEMON Inc.85

Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.

BIO-FD&C CO.,LTD.85

Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.

HANDOK Inc.85

KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition